Natera to Present 16 New Transplant Studies at 2025 World Transplant Congress
Natera, a global leader in cell-free DNA and precision medicine, announced it will present 16 new research datasets at the 2025 World Transplant Congress (WTC), taking place August 2–6 in San Francisco. These studies span kidney, heart, and lung transplantation and represent one of the most comprehensive sets of data to date for Natera’s Prospera® test.
The company’s presentations include five oral sessions and 11 posters, highlighting real-world and clinical trial data supporting the clinical utility of Prospera in transplant monitoring. Key highlights include:
- Trifecta Study Series: Multiple abstracts, including three oral presentations, evaluating Prospera’s performance across kidney, heart, and lung transplants.
- Peer-Reviewed Evidence: Posters featuring recent studies published in the American Journal of Transplantation, including:
- The PEDAL trial, showing Prospera Kidney‘s ability to predict long-term rejection outcomes.
- A study of Prospera Heart with Donor Quantity Score (DQS), validating its accuracy in detecting allograft rejection.
- Therapy Monitoring: An oral presentation on Prospera Kidney‘s role in monitoring chronic antibody-mediated rejection during anti-CD38 therapy, recently published in Kidney International Reports.
We are proud to share 16 presentations across organ types at this major global conference,” said Dr. Sangeeta Bhorade, Chief Medical Officer, Organ Health at Natera. “These findings, along with our growing body of peer-reviewed publications, underscore the clinical value of Prospera in advancing transplant care.
WTC 2025 Presentation Highlights:
Oral Presentations:
- Aug 3: Trifecta-Lung Study – dd-cfDNA and rejection correlations
- Aug 4: U.S. practices in managing costs of kidney paired donation
- Aug 5–6: Defining relationships among tests for heart and kidney antibody-mediated rejection
- Aug 6: Chronic rejection therapy using anti-CD38 monoclonal antibody Daratumumab
Poster Sessions:
- Aug 4–5: Topics include genetic testing in donor selection, DSA-negative rejection diagnosis, and monitoring allograft response across organ types
- Studies explore cell-free DNA (cfDNA) patterns in rejection vs. infection, repeat transplantation, and machine learning for dd-cfDNA trend analysis
About Natera
Natera™ is a global leader in cfDNA and genetic testing across oncology, women’s health, and organ health. With over 300 peer-reviewed publications, Natera aims to integrate personalized diagnostics into routine care for better, earlier interventions. Its CLIA-certified, CAP-accredited labs operate in Austin, TX and San Carlos, CA.
More information: www.natera.com
Let me know if you’d like a version tailored for a press release, newsletter, or social media.
